BridgeBio Pharma Net Profit Margin 2018-2024 | BBIO
BridgeBio Pharma net profit margin from 2018 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
| BridgeBio Pharma Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2024-06-30 |
$0.22B |
$-0.45B |
-206.85% |
| 2024-03-31 |
$0.22B |
$-0.54B |
-245.66% |
| 2023-12-31 |
$0.01B |
$-0.64B |
-6430.00% |
| 2023-09-30 |
$0.01B |
$-0.61B |
-6130.00% |
| 2023-06-30 |
$0.01B |
$-0.57B |
-9550.00% |
| 2023-03-31 |
$0.08B |
$-0.43B |
-544.87% |
| 2022-12-31 |
$0.08B |
$-0.48B |
-616.67% |
| 2022-09-30 |
$0.09B |
$-0.49B |
-550.56% |
| 2022-06-30 |
$0.09B |
$-0.51B |
-559.34% |
| 2022-03-31 |
$0.07B |
$-0.60B |
-838.03% |
| 2021-12-31 |
$0.07B |
$-0.56B |
-814.49% |
| 2021-09-30 |
$0.06B |
$-0.54B |
-955.36% |
| 2021-06-30 |
$0.06B |
$-0.50B |
-798.39% |
| 2020-09-30 |
$0.02B |
$-0.40B |
-1827.27% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.791B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
